Assessing vaccination coverage, timeliness, and its temporal variations among children in a rural area in China

Figures & data

Table 1. Comparison of demographic and socioeconomic characteristics, using Chi-square tests, between the children included and children excluded from this study, Anhua county, Hunan province, southern China

Characteristics	Total n (%)	Children included n (%)	Children excluded n (%)	P-value ^a
Total Sex, Male	5,254 2,691 (51.2)	5,091 2,612 (97.1)	163 79 (2.9)	0.530
Birth Cohort ^b
2004–2007	701 (13.3)	647 (92.3)	54 (7.7)	< 0.001
2008	648 (12.3)	631 (97.4)	17 (2.6)
2009	670 (12.8)	641 (95.7)	29 (4.3)
2010	672 (12.8)	658 (97.9)	14 (2.1)
2011	732 (13.9)	714 (97.5)	18 (2.5)
2012	765 (14.6)	740 (96.7)	25 (3.3)
2014–2015	1,066 (20.3)	1,060 (99.4)	6 (0.6)
Annual household income (US dollars)
<1400	194 (3.7)	185 (95.4)	9 (4.6)	0.032
1400~	960 (18.3)	923 (96.1)	37 (3.9)
2800~	2,912 (55.4)	2,831 (97.2)	81 (2.8)
7000~	1,016 (19.3)	991 (97.5)	25 (2.5)
≥ 14000	164 (3.1)	154 (93.9)	10 (6.1)
Missing	8 (0.2)	7 (87.5)	1 (12.5)

^aP-values based on chi-square tests.

^bThere is no 2013 cohort in the original sero-survey.

Table 2. Vaccination coverage and timeliness for EPI vaccines, by dose. Vaccines scheduled at <12 months are shaded in gray

Vaccine	Introduction time	Dose	Recommended vaccination age	No. of children ^a	Vaccination coverage		Vaccination timeliness		The proportion of children vaccinated on time among children vaccinated
					n	%	n	%
BCG	1978	1	at birth	5091	5032	98.8	4109	80.7	81.7
HepB	2002	1	at birth	5091	5053	99.3	4236	83.2	83.8
		2	1 month	5091	5039	99.0	3474	68.2	68.9
		3	6 months	5091	4986	97.9	2679	52.6	53.7
PV	1978	1	2 months	5091	5062	99.4	3796	74.6	75.0
		2	3 months	5091	5053	99.3	3148	61.8	62.3
		3	4 months	5091	5036	98.9	2805	55.1	55.7
		4	4 years	3291	2852	86.7	976	29.7	34.2
DTP	1978	1	3 months	5091	5039	99.0	3509	68.9	69.6
		2	4 months	5091	5019	98.6	3122	61.3	62.2
		3	5 months	5091	4998	98.2	2451	48.1	49.0
		4	18 months	4967	4654	93.7	1299	26.2	27.9
DT	1978	1	6 years	1919	992	51.7	295	15.4	29.7
MCV	1978	1	8 months	5091	5016	98.5	2853	56.0	56.9
		2	18 months	4967	4777	96.2	1757	35.4	36.8
HepA	2009	1	18 months	4320	3980	92.1	472	10.9	11.9
JEV	2008	1	8 months	4444	4317	97.1	1049	23.6	24.3
		2	2 years	3867	3508	90.7	1053	27.2	30.0
MenA ^b	2008	1	6–18 months	4444	4220	95.0	1093	24.6	25.9
		2	6–18 months	4444	3857	86.8	524	11.8	13.6
MenAC	2008	1	3 years	3610	3257	90.2	1112	30.8	34.1
		2	6 years	1272	565	44.4	122	9.6	21.6

Abbreviations: BCG, Bacillus Calmette-Guérin vaccine; HepB, Hepatitis B vaccine; PV, Poliovirus vaccine; DTP, Diphtheria, tetanus and pertussis vaccine; MCV, Measles containing vaccine; HepA, Hepatitis A vaccine; JEV, Japanese encephalitis vaccine; MenA, Meningococcal polysaccharide vaccine type A; MenAC, Meningococcal polysaccharide vaccine type A and C; DT, Diphtheria and tetanus vaccine.

^aFor each dose of vaccine, the children outside of vaccine age range or without vaccine access were excluded.

^bFor MenA, the vaccination schedule was two doses administered between 6–18 months, with an interval of 3 months, before 2016.

Table 3. Vaccination coverage and timeliness for non-EPI vaccines, by dose, based on the study population (rural children) in Anhua county, Hunan province, southern China

Vaccine	Introduction time	Dose	No. of children^a	Vaccination coverage
				N	%
Hib	2002	1	5091	2340	46.0
		2	5091	1483	29.1
		3	5091	1018	20.0
		4	4967	265	5.3
ORV	2002	1	5091	659	12.9
		2	4967	51	1.0
		3	4514	5	0.1
PCV7	2008	1	4031	7	0.2
		2	4031	2	0.05
		3	4031	0	0.0
		4	4031	0	0.0
VarV	2002	1	4967	1590	32.0

Abbreviations: Hib, Haemophilus influenzae type B vaccine; ORV, Oral rotavirus vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; VarV, Varicella vaccine.

^aFor each dose of vaccines, the children who were either not age-appropriate or, while age-appropriate, did not have access to vaccines were excluded.

Figure 1. Vaccination coverages of EPI vaccines by birth cohort. No data was collected for a 2013 cohort in the original sero-survey study. Each line begins from the cohort in which the vaccine was first introduced to the EPI, and ends with the cohort for which the vaccine is not age-appropriate

(a). EPI vaccines scheduled at <12 months and MenA. (b). EPI vaccines scheduled at ≥12 months

Figure 2. Vaccination coverage of non-EPI vaccines by birth cohort. No data was collected for a 2013 cohort in the original sero-survey study. PCV7 and ORV-3 are omitted due to negligible vaccine coverage across all cohorts

Figure 3. Vaccination timeliness for EPI vaccines, by birth cohort. No data was collected for a 2013 cohort in the original sero-survey study. Each line begins from the cohort in which the vaccine was first introduced to the EPI, and ends with the cohort for which the vaccine is not age-appropriate

(a). EPI vaccines scheduled at <12 months and MenA. (b). EPI vaccines scheduled at ≥12 months.